^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/25/2023
Excerpt:
Bladder Cancerā€¦.Cisplatin ineligible, first-line therapy for locally advanced or metastatic diseaseā€¦.Preferred regimen:...pembrolizumab and enfortumab vedotin-ejfv